Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity

Human and Experimental Toxicology

Volumn 25, Issue 6, 2006, Pages 325-332

  Ghafari, H ^a   Yasa, N ^b   Mohammadirad, A ^a   Dehghan, G ^a   Zamani, M J ^a   Nikfar, S ^a   Khorasani, R ^a   Minaie, B ^c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acetic acid; Cells lipid peroxidation; Inflammatory bowel disease; Mouse; Myeloperoxidase; Oxidative stress; Toxicity; Ziziphora clinopoides

Indexed keywords

ACETIC ACID; FREE RADICAL; HERBACEOUS AGENT; LIPID; MYELOPEROXIDASE; PLANT EXTRACT; PREDNISOLONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; ZIZIPHORA CLINOPOIDES EXTRACT;

ANGIOSPERM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENTERITIS; ENZYME INHIBITION; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ZIZIPHORA CLINOPOIDES;

ACETIC ACID; ANIMALS; INDICATORS AND REAGENTS; INFLAMMATORY BOWEL DISEASES; LIPID PEROXIDATION; MICE; PEROXIDASE; PHYTOTHERAPY; PLANT PREPARATIONS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ANIMALIA; ZIZIPHORA;

EID: 33746025241     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327105ht626oa     Document Type: Article

References (61)

1. Simmonds NJ, Rampton DS. Inflammatory bowel disease - a radical view. Gut 1993; 34: 865-68.
2. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996; 41: 2078-86.
3. Hadjibabaie M, Rastkari N, Rezaie A, Abdollahi M. The adverse drug reaction in the gastrointestinal tract: an overview. Intl J Pharmacol 2005; 1: 1-8.
4. Rozaie A, Taghavi B, Abdollahi M. Biologic management of fistulizing Crohn's disease. Intl J Pharmacol 2005; 1: 17-24.
5. D'Odorico A, Bortolan S, Cardin R, D'Inca R, Martines D, Forronato A, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 1289-94.
6. Schempp H, Toth A, Weiser D, Elstner EF. Antioxidative properties of Iberis amara extracts in biochemical model reactions. Arzneimittelforschung 2003; 53: 568-77.
7. Tuzun A, Erdil A, Inal V, Aydin A, Bagci S, Yesilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002; 35: 569-72.
8. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaiee A. Pesticides and oxidative stress. Med Sci Monit 2004; 10: RA144-47.
9. Jahanshahi C, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004; 49: 1752-57.
10. Barbosa DS, Cecchini R, El Kadri MZ, Rodriguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 2003; 19: 837-42.
11. Hirayama A, Nagase S, Ueda A, Ishizu T, Taru Y, Yoh K, et al. Oxidative stress during leukocyte absorption apheresis. J Clin Apher 2003; 18: 61-66.
12. Ahnfelt-Ronne I, Nielsen OH. The anti-inflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 1987; 21: 191-94.
13. Kvietys PR, Inauen W, Bacon BR, Grisham MB. Xanthine oxidase-induced injury to endothelium: role of intracellular iron and hydroxyl radical. Am J Physiol 1989; 257: H1640-46.
14. Simmonds NJ, Millar AD, Blake DR, Rampton DS. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999; 13: 363-72.
15. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998; 45: 69-73.
16. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-67.
17. Hernandez-Perez M, Rabanal RM, de la Torre MC, Rodriguez B. Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Planta Med 1995; 61: 505-509.
18. Cuppett SL, Hall CA 3rd. Antioxidant activity of the Labiatae. Adv Food Nutr Res 1998; 42: 245-71; review.
19. Wasser S, Ho JM, Ang HK, Tan CE. Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. J Hepatol 1998; 29: 760-71.
20. Hosseinzadeh H, Khodaparast HMH, Shokohizadeh H. Antihyperglycemic effect of Saliva leriifolia Benth leaf and seed extract in mice. Irn J Med Sci 1998; 23: 78-80.
21. Rechinger KH. Flora iranica, Volume 150. Akademische Druck-u. Verlagsanstalt, 1982: 483-85.
22. Ozturk Y, Aydin S, Tocik B, Baser KHC. Effects of essential oils from certain Ziziphora species on swimming performance in mice. Phytother Res 1995; 9: 225-27.
23. Zargari A. Iranian medicinal plants, Volume 4. Tehran University Press, 1995: 103-104.
24. Krawisz JE, Sharon P, Stenson WF. Qualitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984; 87: 1344-50.
25. Jagtap AG, Shirke SS, Phadke AS. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 2004; 90: 195-204.
26. Satho K. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin Chem Acta 1978; 90: 37-43.
27. Sharon P, Stenson WF. Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenterology 1985; 88: 55-63.
28. Elson CO, Cong Y, Brandwein S, Weaver CT, McCabe RP, Mahler M, et al. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann NY Acad Sci 1998; 859: 85-95.
29. MacPherson B, Pfeiffer GJ. Experimental colitis. Digestion 1976; 14: 424-52.
30. Katzung BC. Basic and clinical pharmacology, eighth edition. Appleton and Lange, 2000.
31. Moral GE, Konyalioglu S, Ozturk B. Essential oil composition and antioxidant activity of endemic Ziziphora taurica subsp. Cleonioides. Fitoterapia 2002; 73: 716-18.
32. Kokkalou E, Kapetanidis I. Flavonoids and phenolic acids in Salvia horminum L. (Lamiaceae). Pharm Acta Helv 1988; 63: 90-92.
33. Sezik E, Tumon G. Ziziphora tenuior L., a new source of pulegone. Flav Fragr J 1988; 6: 101-103.
34. Tumen G, Ayhan Z. Antimicrobial activity of essential oils of two Ziziphora species growing in Turkey. Fitoterapia 1992; 63: 264-65.
35. Belyaev NF, Demeubaeva AM. Chromatographic study of the composition of the essential oil of Ziziphora clinopodioides, a vicarious form of Origanum vulgare. Chem Nat Comp 1999; 35: 52-54.
36. Salehi P, Sonboli A, Eftekhar F, Nejad-Ebrahimi S, Yousefzadi M. Essential oil composition, antibacterial and antioxidant activity of the oil and various extracts of Ziziphora clinopodioides subsp. rigida (BOISS.) RECH. f. from Iran. Biol Pharm Bull 2005; 28: 1892-96.
37. Okuda T, Yoshida T, Hatano T. Food phytochemicals for cancer prevention. American Chemical Society, 1994: 132-43.
38. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98: 136-41.
39. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859-61.
40. Allgayer H. Clinical relevance of oxygen radicals in inflammatory bowel disease facts and fashion. Klin Wochenschr Rev 1991; 69: 1001-1003.
41. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33: 6S-15S.
42. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 2004; 49: 1433-37.
43. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003; 201: 17-27.
44. Arnhold J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 2004: 69: 4-9.
45. Le Marchand L. Cancer preventive effects of flavonoids - a review. Biomed Pharmacother 2002; 56: 296-301; review.
46. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999; 129: 758S-67; review.
47. Sanchez de Medina F, Vera B, Galvez J, Zarzuelo A. Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci 2002; 70: 3097-108.
48. Hong T, Jin GB, Cho S, Cyong JC. Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med 2002; 68: 268-71.
49. Martinez-Vazquez M, Ramirez Apan TO, Aguilar H, Bye R. Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata. Planta Med 1996; 62: 137-40.
50. Ramesh M, Rao YN, Rao AV, Prabhakar MC, Rao CS, Muralidhar N, et al. Antinociceptive and anti-inflammatory activity of a flavonoid isolated from Caralluma attenuata. J Ethnopharmacol 1998; 62: 63-66.
51. Villegas I, Alarcon de la Lastra C, Orjales A, La Casa C. A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int Immunopharmacol 2003; 13: 1731-41.
52. Abdollahi M, Chan TS, Subrahmanyam V, O'Brien PJ. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003; 252: 205-11.
53. Abdollahi M, Bahreini-Moghadam A, Emami B, Fooladian F, Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp Biochem Physiol C Toxicol Pharmacol 2003; 135: 331-36.
54. Abdollahi M, Fooladian F, Emami B, Zafari K, Bahreini-Moghadam A. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol 2003; 22: 587-92.
55. Aghababaeian R, Ghazi-Khansari M, Abdi K, Taghadosinejad F, Abdollahi M. Protective effects of sildenafil and dipyridamol from lead-induced lipid peroxidation in perfused rat liver. Intl J Pharmacol 2005; 1: 157-60.
56. Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005; 140: 251-55.
57. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005; 59: 302-306.
58. Zamani MJ, Sharifzadeh M, Rezaie A, Mashayekhi F, Abdollahi M. Effects of sildenafil on rat irritable bowel syndrome. Therapy 2005; 2: 237-42.
59. Ultee A, Kets EP, Smid EJ. Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereus. Appl Environ Microbiol 1999; 65: 4606-10.
60. Hurt S. Essential oils: their antibacterial properties and potential applications in foods - a review. Int J Food Microbiol 2004; 94: 223-53; review.
61. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004; 50: 81-92.